[EN] INHIBITION OF OLIG2 ACTIVITY<br/>[FR] INHIBITION DE L'ACTIVITÉ D'OLIG2
申请人:CURTANA PHARMACEUTICALS INC
公开号:WO2018039621A1
公开(公告)日:2018-03-01
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
Absence of stereoelectronic control in the hydrolysis of fully and partially N-alkylated cyclic amidinium ions
作者:Charles L. Perrin、John D. Thoburn
DOI:10.1021/ja00061a013
日期:1993.4
Deslongchamps' hypothesis of stereoelectroniccontrol states that preferential cleavage of a tetrahedral intermediate occurs when a leaving group is antiperiplanar to two lone pairs. Yet substantial amounts of lactams were produced from hydrolysis of cyclic amidines, through cleavage of the exocyclic C-N bond that is antiperiplanar to only one lone pair and syn to the other. It may be that proton transfer catalyzes
[EN] COMPOUNDS AS RAS INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE RAS ET LEURS UTILISATIONS
申请人:BIOARDIS LLC
公开号:WO2022087624A1
公开(公告)日:2022-04-28
The present disclosure relates generally to compounds and compositions thereof for inhibition of RAS, such as KRAS, HRAS and NRAS, including mutant forms of KRAS, HRAS and NRAS, particularly those harboring a G12C mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung cancer, colorectal cancer, pancreatic cancer, gall bladder cancer, thyroid cancer, and bile duct cancer.
The present invention provides compounds represented by the formula (Ie):
and the formula (If):
wherein each symbol is as defined in the specification.
According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.
A 1,6-β-glucan synthetase inhibitor is provided, having potent growth inhibition and having excellent safety.
A compound is provided, capable of expressing in a wide spectral range and specifically or selectively, an antifungal effect based on its functional mechanism of 1,6-β-glucan synthesis inhibition. Also provided is a drug, especially an antifungal that contains the compound, its salt or their hydrate. Concretely, provided are a compound of the following formula (I), its salt or their hydrate, and a drug or antifungal containing, as the active ingredient, the compound, its salt or their hydrate: